WIRB 20152164
#15823617.0

Parkinson's disease

If you're one of the estimated 5 million people in the world with Parkinson's disease, you'll understand the frustration of this long-term condition, which can greatly affect yours and your family's quality of life.

Treatment for Parkinson's disease focuses on controlling the signs and symptoms for as long as possible. Carbidopa and levodopa are two of the most commonly used medicines, and most people with Parkinson's disease respond well to this combination of medicines in the early stages of their disease.

However, as Parkinson's disease progresses, the effects of carbidopa/levodopa may not last so long in the body. This may lead to increased 'Off' time, when symptoms can get worse.

Find out more about the Accordance study

Contact us to learn more about the Accordance study, or to find out if you, or someone you know, may be eligible to take part

For more information please contact:

Raymond James, BS, RN
Boston University Medical Campus
rcjames@bu.edu
617-638-7745

Accordance study

A new research study for people with Fluctuating Parkinson's disease currently taking Carbidopa/Levodopa

INFORMATION FOR PATIENTS AND CAREGIVERS

accordance

accordance

accordance

Accordance study

A new research study

The Accordance study is investigating a longer-acting platform technology to give Carbidopa/Levodopa to people who have Fluctuating Parkinson's disease. This study will evaluate whether or not a longer-acting capsule can help to reduce the amount of 'Off' time experienced by people with Fluctuating Parkinson's disease. We also want to find out if the study capsule is safe.

Could you, or someone you know, qualify for the study?

People with Parkinson's disease may be able to take part in the Accordance study if they:

- are 30 years of age, or older
- are taking at least 4 doses of levodopa-containing medicine (or 3 doses of Rytary) per day
- have at least 2.5 hours 'Off time' per day during waking hours (including morning loss of movement)

The study capsule

We're investigating Carbidopa/Levodopa in an innovative capsule form called an Accordion Pill™. This dosage form is designed to release carbidopa/levodopa medicine more gradually than other pill forms. The study capsule will be given two or three times daily, and its effects will be compared with Sinemet - an Immediate Release pill form of Carbidopa/Levodopa given at least four times daily.

A placebo, or 'dummy pill' is also being used in this study. The dummy pill does not have any active medicine, but is necessary in order to measure the effect of the study pill in a non-biased way. Using dummy pills means that neither you nor the study team will know if you are taking the study capsule or the Immediate Release Sinemet.

The study is designed so that everyone who takes part will receive treatment for their condition.

How long is the study?

The study has a planned duration of up to 32 weeks. During this time, participants will receive study medicines regularly and visit the clinic for health assessments until the end of the study, unless the study doctor decides that it is no longer appropriate to receive these medicines, or the participant decides to withdraw from the study. Therefore, although there are at least 13 visits in this study, there may be fewer visits.

Why take part?

People that qualify to take part in the Accordance study will receive:

- All study-related care at no charge
- Close monitoring by a physician with experience in Parkinson's disease

It is only through research that new medicines can be developed, and participation in this study may help to advance medical knowledge and improve care for the millions of people coping with Parkinson's disease in the world today.